Atara Biotherapeutics Inc (NASDAQ:ATRA) has been given an average rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.67.

ATRA has been the subject of a number of research reports. Goldman Sachs Group reiterated a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Jefferies Group reiterated a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a research note on Wednesday, January 3rd. Finally, ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th.

Shares of Atara Biotherapeutics (ATRA) traded up $1.45 during midday trading on Friday, hitting $22.15. The stock had a trading volume of 652,200 shares, compared to its average volume of 1,142,237. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $23.00. The stock has a market capitalization of $670.36, a price-to-earnings ratio of -6.38 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). equities research analysts predict that Atara Biotherapeutics will post -4 earnings per share for the current fiscal year.

In other Atara Biotherapeutics news, CFO John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $20.00, for a total value of $640,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $13.47, for a total value of $59,268.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $9,937,721.49. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,788 shares of company stock valued at $2,194,934. 16.20% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC boosted its stake in Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after acquiring an additional 147,061 shares during the period. Perceptive Advisors LLC acquired a new position in Atara Biotherapeutics in the third quarter valued at approximately $581,000. Artal Group S.A. boosted its position in shares of Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after buying an additional 100,000 shares during the period. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $142,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $170,000. Institutional investors own 85.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) Given Average Rating of “Buy” by Brokerages” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-given-average-rating-of-buy-by-brokerages/1804528.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.